403518-14-9

Usage

Uses

Used in Pharmaceutical Industry:
2,5-Pyrrolidinedione, 1-[3-(methyldithio)-1-oxopropoxy]is used as an intermediate in the synthesis of Mertansine-13CD3 (M257802), which is the isotope-labelled analog of Mertansine (M257800). Mertansine is a potent cytotoxic agent that is utilized as the cytotoxic component in antibody-drug conjugates (ADCs). These ADCs are designed to selectively target and destroy cancer cells while minimizing damage to healthy cells.
The use of 2,5-Pyrrolidinedione, 1-[3-(methyldithio)-1-oxopropoxy]in the development of Mertansine-13CD3 highlights its importance in the pharmaceutical industry, particularly in the field of cancer research and treatment. By enabling the synthesis of cytotoxic agents with improved targeting and efficacy, 2,5-Pyrrolidinedione, 1-[3-(methyldithio)-1-oxopropoxy]- contributes to the advancement of cancer therapies and the development of more effective treatments for patients.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 138148-59-1 3-Methyldisulfanyl-propionic acid 

Relevant academic research and scientific papers

CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS

The present invention concerns a process for preparing a multispecific antibody construct, comprising conjugating a functionalized antibody Ab(F)x containing x reactive moieties F, wherein x is an integer in the range 1 – 10, and an immune cell

VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES

The present invention provides antibody-payload conjugates having a payload-to-antibody ratio of 1. The antibody-payload conjugate is according to structure (1): formula (1), wherein: - a, b, c and d are each independently 0 or 1; - e is an integer in the

Antibody medicine conjugate for treating pancreatic cancer and preparation method thereof

The invention provides an antibody medicine conjugate for treating pancreatic cancer and a preparation method thereof, and belongs to the technical field of antitumor medicine. The antibody medicine conjugate is characterized in that a targeted EGFR (Epidermal Growth Factor Receptor) antibody medicine conjugate (LR-DM1) using pancreatic cancer as an adaptation disease is built by using an anti-EGFR monoclonal antibody and using a cytotoxic molecule maytansine derivative DM1 with the specific action mechanism as an effector molecule and a stable thioether connector SMCC(4-(maleinimide) cyclohexanecarboxylic acid N-succinimido ester) as a coupling connector. The antibody medicine conjugate is subjected to systematic in vitro and vivo activity evaluation. Compared with a naked antibody, the LR-DM1 has the equivalent appetency in the antigen level and the cell level, and can be effectively internalized by target cells.

One-pot: N -glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates

Chemoenzymatic transglycosylation catalyzed by endo-S mutants is a powerful tool for in vitro glycoengineering of therapeutic antibodies. In this paper, we report a one-pot chemoenzymatic synthesis of glycoengineered Herceptin using an egg-yolk sialylglycopeptide (SGP) substrate. Combining this one-pot strategy with novel non-natural SGP derivatives carrying azido or alkyne tags, glycosite-specific conjugation was enabled for the development of new antibody-drug conjugates (ADCs). The site-specific ADCs and semi-site-specific dual-drug ADCs were successfully achieved and characterized with SDS-PAGE, intact antibody or ADC mass spectrometry analysis, and PNGase-F digestion analysis. Cancer cell cytotoxicity assay revealed that small-molecule drug release of these ADCs relied on the cleavable Val-Cit linker fragment embedded in the structure. These results represent a new approach for glycosite-specific and dual-drug ADC design and rapid synthesis, and also provide the structural requirement for their biologic activities.

Semisynthetic Maytansine analogues for the targeted treatment of cancer

Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells. A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized. The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied. Several of these maytansinoids were found to be even more potent in vitro than maytansine. The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.